First in Human Study Evaluating Single Ascending Oral Doses of YCT-529 in Healthy Males

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 20, 2023

Primary Completion Date

June 18, 2024

Study Completion Date

June 18, 2024

Conditions

Male Contraception

Interventions

DRUG

YCT-529

Single oral dose (planned doses of 10, 30, 90 and 200 mg; dose levels will not exceed 250 mg

DRUG

YCT-529 Placebo

Trial Locations (1)

Quotient Sciences, Nottingham

All Listed Sponsors

lead

YourChoice Therapeutics, Inc.

INDUSTRY

NCT06094283 - First in Human Study Evaluating Single Ascending Oral Doses of YCT-529 in Healthy Males | Biotech Hunter | Biotech Hunter